NCT06970678 Combining Dexmedetomidine Infusion and Paragastric Autonomic Neural Block to Enhance Postoperative Recovery in Patients Undergoing Laparoscopic Sleeve Gastrectomy
| NCT ID | NCT06970678 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Alexandria University |
| Condition | Laparoscopic Sleeve Gastrectomy (LSG) |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2025-04-04 |
| Primary Completion | 2025-06-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 46 participants in total. It began in 2025-04-04 with a primary completion date of 2025-06-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if combining Dexmedetomidine infusion and paragastric autonomic neural block will enhance the postoperative recovery of patients undergoing laparoscopic sleeve gastrectomy. The main questions it aims to answer are: Will combining the two techniques (Dexmedetomidine infusion and paragastric autonomic neural block) improve the quality of recovery? Will opioid consumption postoperatively decrease after combining those two techniques? Will the patients be able to start mobilizing sooner after surgery? Will the patient encounter less incidence of nausea and vomiting? Researchers will asses the quality of the patients' recovery by reviewing the Quality of recovery 40 (QoR 40) questionnaire filled by the patients, assessing hemodynamic parameters intra- and postoperatively, recording the opioids consumed by the patients in the postoperative period, recording the time to first mobilization of the patient, and recording the incidence of nausea and vomiting.
Eligibility Criteria
Inclusion Criteria: 1. ASA II-III 2. 18-60 years 3. BMI of 35-50 kg/m² Exclusion Criteria: 1. Patients with chronic pain disorders 2. Patients using gabapentin, chronic opioid users 3. Patients on anticoagulant therapy 4. Patients with history of upper gastrointestinal system surgery 5. Patients with liver, kidney, cardiovascular diseases 6. Patients with allergy to dexmedetomidine or bupivacaine
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06970678 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Laparoscopic Sleeve Gastrectomy (LSG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06970678 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06970678 currently recruiting?
Yes, NCT06970678 is actively recruiting participants. Contact the research team at m_mohamed165@alexmed.edu.eg for enrollment information.
Where is the NCT06970678 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT06970678 clinical trial?
NCT06970678 is sponsored by Alexandria University. The trial plans to enroll 46 participants.